NDAORALCAPSULE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POLYCILLIN is an oral ampicillin capsule formulation developed by Bristol Myers Squibb, currently in pre-launch stage as an NDA product. Ampicillin is a broad-spectrum beta-lactam antibiotic used to treat bacterial infections across multiple body systems. The drug works by inhibiting bacterial cell wall synthesis, making it bactericidal against susceptible gram-positive and gram-negative organisms.
Pre-Launch
As a pre-launch NDA product, this represents a nascent commercial opportunity with team-building and market preparation activities underway at Bristol Myers Squibb.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on POLYCILLIN offers career opportunities across 557 linked positions, with emphasis on manufacturing scale-up, regulatory approval strategy, and legal/compliance functions during the pre-launch phase. Management and director-level roles dominate the opportunity set, reflecting the organizational infrastructure needed to bring a legacy molecule to market.
Manager
Worked on POLYCILLIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.